BioStem Technologies, Inc. (BSEM)
OTCMKTS · Delayed Price · Currency is USD
5.80
-0.16 (-2.68%)
Aug 22, 2025, 4:00 PM EDT
BioStem Technologies Revenue
BioStem Technologies had revenue of $49.30M in the quarter ending June 30, 2025, a decrease of -33.82%. This brings the company's revenue in the last twelve months to $307.26M, up 133.77% year-over-year. In the year 2024, BioStem Technologies had annual revenue of $301.83M with 1,708.93% growth.
Revenue (ttm)
307.26M
Revenue Growth
+133.77%
P/S Ratio
0.32
Revenue / Employee
9.31M
Employees
33
Market Cap
97.13M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 301.83M | 285.14M | 1,708.93% |
Dec 31, 2023 | 16.69M | 9.81M | 142.69% |
Dec 31, 2022 | 6.88M | 2.53M | 58.38% |
Dec 31, 2021 | 4.34M | 4.03M | 1,284.88% |
Dec 31, 2017 | 313.45K | -293.78K | -48.38% |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2014 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2011 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2010 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Veradigm | 588.02M |
Glass House Brands | 221.55M |
Tian'an Technology Group | 1.78M |
Elite Pharmaceuticals | 105.45M |
American Oncology Network | 1.76B |
Northwest Biotherapeutics | 1.09M |
Silence Therapeutics | 27.17M |
Global Cord Blood | 196.10M |
BioStem Technologies News
- 3 days ago - BioStem Technologies Announces Insider Share Purchase by Chairman and Chief Executive Officer - GlobeNewsWire
- 9 days ago - BioStem Technologies, Inc. (BSEM) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 10 days ago - BioStem Technologies Reports Preliminary Second Quarter 2025 Financial Results - GlobeNewsWire
- 10 days ago - BioStem Technologies Appoints Brandon Poe as Chief Financial Officer - GlobeNewsWire
- 5 weeks ago - BioStem Technologies Provides Comments on CMS CY 2026 Proposed Medicare Reimbursement Rule Changes for Skin Substitutes - GlobeNewsWire
- 6 weeks ago - BioStem Technologies to Present at the Advanced Wound Care Summit in Boston on July 15, 2025, at 2:00 PM ET - GlobeNewsWire
- 2 months ago - BioStem Technologies: Huge Growth, Poised To Help Wound Care Field - Seeking Alpha
- 3 months ago - Ernst & Young (EY) US Announces Jason Matuszewski, CEO of BioStem Technologies, as an Entrepreneur Of The Year® 2025 Florida Award finalist - GlobeNewsWire